The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.

Autor:	Sauter JL; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: sauterj@mskcc.org., Dacic S; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Galateau-Salle F; MESOPATH Centre Leon Berard, Lyon, France; Unit of Cancer Research Center INSERM U1052-CNRS5286R, Lyon, France., Attanoos RL; Department of Cellular Pathology, University Hospital of Wales and School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom., Butnor KJ; Department of Pathology & Laboratory Medicine, The University of Vermont Medical Center, Burlington, Vermont., Churg A; Department of Pathology and Laboratory Medicine, Vancouver General Hospital and The University of British Columbia, Vancouver, British Columbia, Canada., Husain AN; Department of Pathology, The University of Chicago, Chicago, Illinois., Kadota K; Department of Pathology, Faculty of Medicine, Shimane University, Izumo, Japan., Khoor A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida., Nicholson AG; Royal Brompton and Harefield Hospitals, and National Heart and Lung Institute, Imperial College, London, United Kingdom., Roggli V; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Schmitt F; RISE@CINTESIS, Medical Faculty of Porto University, Porto, Portugal; Unit of Molecular Pathology of IPATIMUP, Porto University Medical School, Porto, Portugal., Tsao MS; Department of Pathology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Travis WD; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 May; Vol. 17 (5), pp. 608-622. Date of Electronic Publication: 2022 Jan 10.
DOI:	10.1016/j.jtho.2021.12.014
Abstrakt:	Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2) well-differentiated papillary mesothelioma has been renamed well-differentiated papillary mesothelial tumor given growing evidence that these tumors exhibit relatively indolent behavior; (3) localized and diffuse mesothelioma no longer include the term "malignant" as a prefix; (4) mesothelioma in situ has been added to the 2021 classification because these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in situ hybridization; (5) the three main histologic subtypes (i.e., epithelioid, biphasic, and sarcomatoid) remain the same but architectural patterns and cytologic and stromal features are more formally incorporated into the 2021 classification on the basis of their prognostic significance; (6) nuclear grading for epithelioid diffuse mesothelioma is introduced, and it is recommended to record this and other histologically prognostic features in pathology reports; (7) BAP1, EZH2, and MTAP immunohistochemistry have been found to be useful in separating benign mesothelial proliferations from mesothelioma; (8) biphasic mesothelioma can be diagnosed in small biopsies having both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and (9) the most frequently altered genes in diffuse pleural mesothelioma include BAP1, CDKN2A, NF2, TP53, SETD2, and SETDB1. (Copyright © 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu